title: Preoperative platelet/lymphocyte ratio is a superior prognostic factor compared to other systemic inflammatory response markers in ovarian cancer patients.
abstract: The aim of the present study was to determine the most meaningful preoperative prognostic factor of cancer-related death in ovarian cancer patients by comparing potentially prognostic systemic inflammatory response (SIR) markers. The levels of fibrinogen, albumin, C-reactive protein (CRP), and serum cancer antigen-125 (CA-125) and the neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) were evaluated in 190 ovarian cancer patients to identify predictors of overall survival (OS) and progression-free survival (PFS) using univariate and multivariate analyses. Patients with a PLR >203 had a shorter PFS and OS than the patients in PLR ≤203 group (11 vs. 24 months and 28 vs. 64 months). Univariate analyses revealed that tumor stage, postoperative residual tumor mass, ascites, and the levels of all SIR markers were associated with PFS and OS. Multivariate analysis revealed that PLR was independently associated with PFS (hazard ratio [HR] 1.852, 95% confidence interval [CI] 1.271-2.697, P = 0.001) and OS (HR 2.158, 95%CI 1.468-3.171, P < 0.001), as well as tumor stage and postoperative residual tumor mass. In contrast, fibrinogen remained significant only for PFS (HR 1.724, 95%CI 1.197-2.482, P = 0.003). Patients with a PLR >203 were more prone to have advanced tumor stage (P = 0.002), postoperative residual tumor mass >2 cm (P = 0.032), malignant ascites (P < 0.001), and all the other elevated SIR markers (P < 0.001). Preoperative PLR is superior to other SIR markers (CA-125, NLR, fibrinogen, CRP, and albumin) as a predictor of survival in ovarian cancer patients.
authors.affiliation: Department of Medical Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.|Department of Medical Oncology, The Sixth People's Hospital of Chengdu, Chengdu, 610051, China.
authors.forename: Wei-wei
authors.initials: WW
authors.lastname: Zhang
authors.affiliation: Department of Medical Oncology, Dongguan People's Hospital, Dongguan, 523059, China.
authors.forename: Ke-jun
authors.initials: KJ
authors.lastname: Liu
authors.affiliation: Department of Medical Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
authors.forename: Guo-lin
authors.initials: GL
authors.lastname: Hu
authors.affiliation: Department of Medical Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. wjliang22@126.com.
authors.forename: Wei-jiang
authors.initials: WJ
authors.lastname: Liang
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood*; D001792:Blood Platelets; D002097:C-Reactive Protein / Q000378:metabolism; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007249:Inflammation / Q000097:blood* / Q000473:pathology; D053208:Kaplan-Meier Estimate; D008214:Lymphocytes; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000097:blood* / Q000473:pathology; D011379:Prognosis
chemical_list: D015415:Biomarkers; D002097:C-Reactive Protein
keywords: Ovarian cancer; Platelet/lymphocyte ratio; Prognostic factor; Systemic inflammatory response markers